Ivana Savic

Prof. Dr. Ivana Savic


Research Focus & Metrics

Academic Career Length

11Years (2016-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2017 in Annals of Thoracic Medicine
Verified
Journal Article
Open access
PDF file
ISIvana Savic
Ivana Savic
MSMihailo Stjepanovic
Mihailo Stjepanovic
DMDragan Mitrovic
Dragan Mitrovic
Introduction: Lung cancer is among leading causes of death worldwide. Different histological types of the lung carcinoma show significant differences in behavior. Objectives: The aim of this study is to determine the distribution patterns of metastases of different lung cancer histological types in autopsied individuals. Methods: Protocols from all autopsies performed at the Institute of Pathology from 2008 till 2014 were reviewed retrospectively, and information on individuals' age, sex, histological type of primary lung cancer, presence and location of metastases, and causes of death were recorded. Results: More than 90% of the individuals with lung cancer metastases were older than 50 years (mean age: 64.5 ± 10.3), with two-fold male predominance. The most frequent histological type in both sexes was adenocarcinoma (48%). Although, in general, hematogenous metastases were mostly found in the liver and adrenal glands, various histological types of lung cancer show specific dissemination patterns. Metastases in adrenal glands derived mostly from adenocarcinoma and large-cell carcinoma. Metastases in the intestines most frequently originated from large-cell carcinoma (P = 0.01). Metastatic complications and bronchopneumonia were the most frequent causes of death. Conclusions: While, overall, the most frequent hematogenous metastases occur in the liver and adrenal glands, various histological types of lung cancer show specific dissemination patterns. Knowing distribution of metastases is essential for making algorithms of treatment, as well as for improving clinical assessment of the patients with unclear clinical findings and suspicion on occult primary lung cancer.

28 January 2022 in Journal of Clinical Medicine
Verified
Journal Article
Open access
PDF file
Milan RadovanovicMilan Radovanovic
Milan Radovanovic
Dorde JevticDorde Jevtic
Dorde Jevtic
ACAndrew D. Calvin
Andrew D. Calvin
MPMarija Petrovic
Marija Petrovic
MPMargaret R Paulson
Margaret R Paulson
Igor DumicIgor Dumic
Igor Dumic
Cardiac involvement in drug reaction with eosinophilia and systemic symptoms (DS) is rare but associated with high mortality. The aim of this research was to systematically review case reports by PRISMA guidelines in order to synthetize the knowledge of cardiac manifestations of DS. We identified 42 cases from 36 case reports. Women were two times more affected than men. Two-thirds of patients had cardiac manifestation in the initial phase of the disease, while in one-third of cases cardiac manifestations developed later (mean time of 70 ± 63 days). The most common inciting medications were minocycline (19%) and allopurinol (12%). In 17% of patients, the heart was the only internal organ affected, while the majority (83%) had at least one additional organ involved, most commonly the liver and the kidneys. Dyspnea (55%), cardiogenic shock (43%), chest pain (38%), and tachycardia (33%) were the most common cardiac signs and symptoms reported. Patients frequently had an abnormal ECG (71.4%), and a decrease in left ventricular ejection fraction was the most common echocardiographic finding (45%). Endomyocardial biopsy or histological examination at autopsy was performed in 52.4%, with the predominant finding being fulminant eosinophilic myocarditis with acute necrosis in 70% of those biopsied. All patients received immunosuppressive therapy with intravenous steroids, while non-responders were more likely to have received IVIG, cyclosporine, mycophenolate, and other steroid-sparing agents (60%). Gender and degree of left ventricular systolic dysfunction were not associated with outcomes, but short latency between drug exposure and the first DRESS symptom onset (<15 days) and older age (above 65 years) was associated with death. This underscores the potential importance of heightened awareness and early treatment.

1 January 2016 in Annals of Saudi Medicine
Verified
Journal Article
Open access
ISIvana Savic
Ivana Savic
VTVesna Trifunovic-Skodric
Vesna Trifunovic-Skodric
DMDragan Mitrovic
Dragan Mitrovic
Miliary tuberculosis (TB) usually presents with atypical clinical manifestations; thus it is often recognized only at autopsy. Our objectives were to study the frequency of MT diagnosed at autopsy and determine clinical diagnoses that masked TB, as well as causes of death and comorbidities. Retrospective study of all autopsies performed between 2008 and 2014. Institute of Pathology, Belgrade, Serbia. in subjects where autopsy showed the presence of MT that was not recognized clinically, we recorded the clinical diagnoses (presumed causes of death) as reported in autopsy request forms, as well as actual cause of death and comorbidities as determined at autopsy. Clinically unrecognized MT. The total number of autopsies in this period was 6206. thirty-five individuals showed clinically unrecognized MT (0.56% of all autopsies, age: 62.2 [17.2] years, M:F=2:3). Common clinical diagnoses masking pulmonary MT were exacerbation of COPD (25%) and pulmonary thromboembolism (25%), with common radiological presentation of diffuse pulmonary infiltrates (56.3%). Dominant clinical diagnoses in patients with generalized MT were adult respiratory distress syndrome, sepsis, gastrointestinal bleeding and meningoencephalitis. Disseminated MT was often associated with secondary anemia or thrombocytopenia (15.8%) and recent surgery (15.8%). Frequent comorbidities included chronic renal failure and malignancies, whereas MT was a dominant cause of death. Greater awareness of MT is needed to improve recognition in clinical settings. In particular, MT should be considered in patients with atypical clinical presentation and diffuse pulmonary infiltrates on chest X-ray, particularly if they have chronic renal failure, malignancy, hematological disorders or a history of recent surgery. None.

26 May 2021 in Acta Medica Academica
Verified
Journal Article
Open access
PDF file
ISIvana Savic
Ivana Savic
JMJeffrey Myers
Jeffrey Myers
In this review, we summarize current approaches to diagnosis of malignant pleural mesothelioma, focusing on the distinction from benign mesothelial proliferations and other malignant tumors. Current recommendations for reporting histological sub-type and tumor grade are also reviewed. Particular emphasis is placed on immunohistochemical and molecular tools that may help in establishing the diagnosis of mesothelioma with greater confidence. Immunohistochemical stains for BRCA1-associated protein (BAP1) and methylthioadenosine phosphorylase (MTAP) and homozygous deletion of p16 using fluorescence in situ hybridization (FISH) are emphasized as important methods for distinguishing benign from malignant mesothelial prolifera- tions.Conclusions. Diffuse malignant pleural mesothelioma is a heterogeneous group of aggressive pleural tumors for which histological classification plays an increasingly important role in patient management. Stage and resectability remain key drivers of therapeutic strategies and outcomes. There is an increasingly robust suite of diagnostic tools, including immunohistochemical stains for BAP1 and MTAP and p16 FISH, for differentiating benign from malignant mesothelial proliferations in cytology and tissue specimens.

1 January 2018 in Medicinski podmladak
Verified
Journal Article
Open access
PDF file
ISIvana Savic
Ivana Savic
DODejan Oprić
Dejan Oprić
Immune checkpoints are receptor-ligand interactions that either enhance or turn down the activation of T-lymphocytes. Among them, the interaction of Programmed death receptor-1 (PD-1) and Programmed death ligand-1 (PD-L1) shows suppressive effect of T-lymphocytes, preventing over activation of T-lymphocytes in inflammation. However, some tumor cells can also express PD-L1 and use it as a strategy to escape the host's immune response, by binding to PD-1 on T-lymphocytes and inducing their energy and apoptosis. Hence, a promising approach in cancer therapy would be focused on preventing the tumor cells' PD-L1 from binding to PD-1 of immune cells by application of monoclonal antibodies against either PD-1 or PD-L1. These novel drugs are known as PD-1/PD-L1 inhibitors, and have been tested in patients with non-small cell lung cancer (NSCLC), particularly in advanced stages of the disease. Compared to conventional chemotherapy, PD-1/PD-L1 inhibitors showed fewer adverse effects, and presented encouraging results in terms of improved survival of NSCLC patients, mostly when used as a second line therapy. The therapeutic agents that inhibit PD-1/PD-L1 binding will have a major clinical value if tumor cells express PD-L1 on their membranes. Therefore, reliable interpretation of PD-L1 expression in tumors is needed for optimal selection of patients who would benefit from PD-1/PD-L1 inhibitors. However, PD-L1 as a biomarker needs further improvement, since the estimation of PD-L1 expression is dependent on several factors, such as number of analyzed tumor cells, used antibody, cut-off values.

1 January 2022 in Medicinski podmladak
Verified
Journal Article
Open access
PDF file
ISIvana Savic
Ivana Savic
NINebojša Ivanović
Nebojša Ivanović
DODejan Oprić
Dejan Oprić
Gap junctions are intercellular connections that enable direct communication between neighboring cells. They are important in tissue homeostasis, cell growth, and differentiation. They are composed of connexin proteins, of which the most common and most studied is connexin 43. The role of connexin 43 in the development and progression of tumors is contradictory. The aim of this paper is to summarize the current state of knowledge on the expression of connexin 43 in various primary and secondary tumors, in order to explain its role in the development and progression of malignant tumors. Previous studies have examined the expression of connexin 43 in various primary and secondary tumors, as well as its association with prognosis. The expression of connexin 43 has been shown to be associated with various aspects of tumor behavior. However, it has been shown that the expression of connexin 43 differs between different types and localizations of tumors, as well as between different stages in tumor progression, which indicates the complex role of connexin 43 in tumor evolution. Since gap junctions play a role in carcinogenesis, invasion, and metastasis of malignant cells, further studies should clarify whether connexin 43 can be used as a diagnostic biomarker.